PharmaCom BioVet Establishing a Proprietary Canine DLA Registry

  PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is
pleased to announce that the Company is in the process of establishing a
proprietary Dog Leukocyte Antigen Registry (DLA). DLA typing is used to
tissue-type canines.  As in humans, dogs have many tissue types that are
incompatible and lead to rejection when cells, such as stem cells or
tissue, are transplanted from one canine to another.  Certain cancer
treatments for dogs involve cell transplant and a tissue type registry of
donors is not readily available.  Establishing a proprietary registry will
allow for accelerated treatments and compatibility between some donors and
recipients resulting in the potential of higher success rates.

"We will be establishing a Canine Donor Registry for use by PharmaCom BioVet to increase the number of canines being treated for lymphoma. This Canine Donor Registry will also be available on a fee basis to other academic and private facilities worldwide," stated Gary Berthold, President of PharmaCom BioVet.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. has positioned itself to become a leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management specializes in Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that enable animals suffering from cancer potentially greater life expectancy and decreased suffering. To learn more, please go to the Corporations Web site www.pharmacombiovet.com

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

Contact: Investor Relations Tel: [phone] URL: http://www.PharmaComBioVet.com